Literature DB >> 22710134

X-inactivation in Fabry disease.

Deborah Elstein1, Ella Schachamorov, Rachel Beeri, Gheona Altarescu.   

Abstract

BACKGROUND: Fabry disease is one of three X-linked lysosomal disorders. Because of X-chromosome inactivation (XCI), wherein there is (random) transcriptional silencing of one of the X-chromosomes in each female cell, females are mosaic for the expression of (some) X-linked genes. Thus, based on penetrance and expression, some females heterozygous for Fabry disease are symptomatic but not to the same degree as hemizygous males. The purpose of this study was to ascertain whether skewed X-inactivation favoring the mutant α-galactosidase A allele exists in our cohort of female heterozygotes of Fabry disease.
METHOD: All patients were evaluated by physical examination and ascribed disease-specific severity sub-scores for each of the four categories (cardiac, renal, neurological, general) and a total score using the Mainz Severity Score Index (MSSI). Blood samples were drawn for enzymatic activity of α-galactosidase A and for DNA extraction for analysis for α-galactosidase A mutations. XCI ratios were determined from peripheral blood leukocyte samples. The X-chromosome inactivation ratio was determined in each heterozygote.
RESULTS: Of 77 samples, only 18.2% were highly skewed (80/20). Only 14.3% of samples with nonsense mutations were highly skewed. There were no correlations between the XCI ratios and age, enzymatic activity of α-galactosidase A, MSSI sub-scores or total score, or with the clinical signs of cardiac involvement, neuropathic pain, or proteinuria.
CONCLUSION: These findings are comparable with others in Fabry disease, i.e., essentially the same as seen in normal non-elderly female population, raising the question of the mechanism underlying symptomatic phenotypic expression in heterozygous females with Fabry disease.
Copyright © 2012 Elsevier B.V. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2012        PMID: 22710134     DOI: 10.1016/j.gene.2012.06.013

Source DB:  PubMed          Journal:  Gene        ISSN: 0378-1119            Impact factor:   3.688


  12 in total

1.  Characterization of Classical and Nonclassical Fabry Disease: A Multicenter Study.

Authors:  Maarten Arends; Christoph Wanner; Derralynn Hughes; Atul Mehta; Daniel Oder; Oliver T Watkinson; Perry M Elliott; Gabor E Linthorst; Frits A Wijburg; Marieke Biegstraaten; Carla E Hollak
Journal:  J Am Soc Nephrol       Date:  2016-12-15       Impact factor: 10.121

Review 2.  Dosage Compensation in Females with X-Linked Metabolic Disorders.

Authors:  Patrycja Juchniewicz; Ewa Piotrowska; Anna Kloska; Magdalena Podlacha; Jagoda Mantej; Grzegorz Węgrzyn; Stefan Tukaj; Joanna Jakóbkiewicz-Banecka
Journal:  Int J Mol Sci       Date:  2021-04-26       Impact factor: 5.923

3.  Mosaicism of podocyte involvement is related to podocyte injury in females with Fabry disease.

Authors:  Michael Mauer; Emily Glynn; Einar Svarstad; Camilla Tøndel; Marie-Claire Gubler; Michael West; Alexey Sokolovskiy; Chester Whitley; Behzad Najafian
Journal:  PLoS One       Date:  2014-11-11       Impact factor: 3.240

4.  Multicenter Female Fabry Study (MFFS) - clinical survey on current treatment of females with Fabry disease.

Authors:  Malte Lenders; Julia B Hennermann; Christine Kurschat; Arndt Rolfs; Sima Canaan-Kühl; Claudia Sommer; Nurcan Üçeyler; Christoph Kampmann; Nesrin Karabul; Anne-Katrin Giese; Thomas Duning; Jörg Stypmann; Johannes Krämer; Frank Weidemann; Stefan-Martin Brand; Christoph Wanner; Eva Brand
Journal:  Orphanet J Rare Dis       Date:  2016-06-29       Impact factor: 4.123

5.  Case report of a 45-year old female Fabry disease patient carrying two alpha-galactosidase A gene mutation alleles.

Authors:  Daniel Oder; Dorothee Vergho; Georg Ertl; Christoph Wanner; Peter Nordbeck
Journal:  BMC Med Genet       Date:  2016-07-19       Impact factor: 2.103

6.  Fabry disease and incidence of cancer.

Authors:  Sarah Bird; Efthymios Hadjimichael; Atul Mehta; Uma Ramaswami; Derralynn Hughes
Journal:  Orphanet J Rare Dis       Date:  2017-09-06       Impact factor: 4.123

Review 7.  DNA methylation impact on Fabry disease.

Authors:  Teodolinda Di Risi; Roberta Vinciguerra; Mariella Cuomo; Rosa Della Monica; Eleonora Riccio; Sirio Cocozza; Massimo Imbriaco; Giovanni Duro; Antonio Pisani; Lorenzo Chiariotti
Journal:  Clin Epigenetics       Date:  2021-02-02       Impact factor: 6.551

Review 8.  Fabry Disease: Molecular Basis, Pathophysiology, Diagnostics and Potential Therapeutic Directions.

Authors:  Ken Kok; Kimberley C Zwiers; Rolf G Boot; Hermen S Overkleeft; Johannes M F G Aerts; Marta Artola
Journal:  Biomolecules       Date:  2021-02-12

9.  IgA nephropathy suspected to be combined with Fabry disease or Alport syndrome: a case report.

Authors:  Wen Hao; Lina Ao; Chenli Zhang; Lei Zhu; Deqiong Xie
Journal:  J Int Med Res       Date:  2019-12-16       Impact factor: 1.671

10.  Novel GLA Deletion in a Cypriot Female Presenting with Cornea Verticillata.

Authors:  Theodoros Georgiou; Gavriella Mavrikiou; Angelos Alexandrou; Elena Spanou-Aristidou; Isavella Savva; Theodoros Christodoulides; Maria Krasia; Violetta Christophidou-Anastasiadou; Carolina Sismani; Anthi Drousiotou; George A Tanteles
Journal:  Case Rep Genet       Date:  2016-03-30
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.